CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue
Research and development	€ 0	€ 0	€ 28	€ 0
Grants	12	242	401	370
Total revenue	12	242	429	370
Expenses
Research and development	215	295	789	720
General and administrative	254	243	875	770
Other (income) expense	(106)	122	(47)	165
Total expenses	363	660	1,617	1,655
Operating loss	(351)	(418)	(1,188)	(1,285)
Interest expense	679	671	2,030	2,004
Loss before income tax provision	(1,030)	(1,089)	(3,218)	(3,289)
Income tax provision	(8)	(5)	(15)	(15)
Net loss	(1,038)	(1,094)	(3,233)	(3,304)
Other Comprehensive Income
Foreign currency translation adjustment	(2)	5	5	11
Comprehensive loss	€ (1,040)	€ (1,089)	€ (3,228)	€ (3,293)
Basic and dilutive earnings per share	€ (0.00)	€ (0.00)	€ (0.01)	€ (0.01)
Weighted average number of shares used in per share calculations	303,757,622	303,757,622	303,757,622	303,757,622